Spots Global Cancer Trial Database for recurrent squamous cell lung carcinoma

Every month we try and update this database with for recurrent squamous cell lung carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches	NCT02785913	Recurrent Squam... Stage IV Squamo...	Laboratory Biom... Taselisib	18 Years -	SWOG Cancer Research Network
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer	NCT02785939	CCND1 Gene Ampl... CCND2 Gene Ampl... CCND3 Gene Ampl... CDK4 Gene Ampli... Recurrent Squam... Stage IV Squamo...	Docetaxel Laboratory Biom... Palbociclib	18 Years -	SWOG Cancer Research Network
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches	NCT02926638	MET Positive Recurrent Squam... Stage IV Squamo...	Erlotinib Hydro... Laboratory Biom... Rilotumumab	18 Years -	SWOG Cancer Research Network
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers	NCT02766335	Recurrent Squam... Stage IV Squamo...	Docetaxel Durvalumab Laboratory Biom...	18 Years -	SWOG Cancer Research Network
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer	NCT02785939	CCND1 Gene Ampl... CCND2 Gene Ampl... CCND3 Gene Ampl... CDK4 Gene Ampli... Recurrent Squam... Stage IV Squamo...	Docetaxel Laboratory Biom... Palbociclib	18 Years -	SWOG Cancer Research Network
Lung-MAP S1400K: c-MET Positive	NCT03574753	Recurrent Squam... Stage IV Squamo...	ABBV-399	18 Years -	SWOG Cancer Research Network
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches	NCT02785913	Recurrent Squam... Stage IV Squamo...	Laboratory Biom... Taselisib	18 Years -	SWOG Cancer Research Network
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers	NCT02785952	Recurrent Squam... Stage IV Squamo...	Ipilimumab Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A...	18 Years -	SWOG Cancer Research Network
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches	NCT02926638	MET Positive Recurrent Squam... Stage IV Squamo...	Erlotinib Hydro... Laboratory Biom... Rilotumumab	18 Years -	SWOG Cancer Research Network
Lung-MAP S1400K: c-MET Positive	NCT03574753	Recurrent Squam... Stage IV Squamo...	ABBV-399	18 Years -	SWOG Cancer Research Network
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer	NCT03377556	ATM Gene Mutati... ATR Gene Mutati... BARD1 Gene Muta... BRCA1 Gene Muta... BRCA2 Gene Muta... BRIP1 Gene Muta... CHEK1 Gene Muta... CHEK2 Gene Muta... FANCA Gene Muta... FANCC Gene Muta... FANCD2 Gene Mut... FANCF Gene Muta... FANCM Gene Muta... NBN Gene Mutati... PALB2 Gene Muta... RAD51 Gene Muta... RAD51B Gene Mut... RAD54L Gene Mut... Recurrent Squam... RPA1 Gene Mutat... Stage IV Squamo...	Laboratory Biom... Pharmacological... Talazoparib	-	SWOG Cancer Research Network
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer	NCT02965378	FGFR1 Gene Ampl... FGFR1 Gene Muta... FGFR2 Gene Ampl... FGFR2 Gene Muta... FGFR3 Gene Ampl... FGFR3 Gene Muta... Recurrent Squam... Stage IV Squamo...	Docetaxel FGFR Inhibitor ... Laboratory Biom...	25 Years -	SWOG Cancer Research Network
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer	NCT03373760	Recurrent Squam... Stage IV Squamo...	Durvalumab Laboratory Biom... Tremelimumab	-	SWOG Cancer Research Network
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer	NCT00946712	Recurrent Large... Recurrent Lung ... Recurrent Squam... Stage IV Large ... Stage IV Lung A... Stage IV Squamo...	Bevacizumab Carboplatin Cetuximab Laboratory Biom... Paclitaxel	18 Years -	SWOG Cancer Research Network
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers	NCT02766335	Recurrent Squam... Stage IV Squamo...	Docetaxel Durvalumab Laboratory Biom...	18 Years -	SWOG Cancer Research Network
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches	NCT02926638	MET Positive Recurrent Squam... Stage IV Squamo...	Erlotinib Hydro... Laboratory Biom... Rilotumumab	18 Years -	SWOG Cancer Research Network
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer	NCT02785939	CCND1 Gene Ampl... CCND2 Gene Ampl... CCND3 Gene Ampl... CDK4 Gene Ampli... Recurrent Squam... Stage IV Squamo...	Docetaxel Laboratory Biom... Palbociclib	18 Years -	SWOG Cancer Research Network

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: